---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039391"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:47:25.102090+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PepGen Q2 net loss $19.5M; cash $147M; FDA clinical hold on DM1 trial continues

## Summary
- Net loss of $19.5M for Q2 2023 vs $17.3M YoY; R&D expense $16.9M, G&A $4.2M.
- Cash and equivalents $147.0M as of June 30, 2023; runway into early 2025.
- FDA clinical hold remains on IND for PGN-EDODM1 Phase 1 study; working to lift.
- Phase 2 CONNECT1-EDO51 open-label MAD study dosing patients in Canada H2 2023.
- Phase 2 CONNECT2-EDO51 multinational RCT expected to initiate H2 2023; initial data mid-2024.

## SEC filing metadata
- accession: 0000950170-23-039391
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017023039391/0000950170-23-039391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017023039391/pepg-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039391
- JSON: https://secwatch.observer/filing/0000950170-23-039391.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039391.txt

## Key facts
- Earnings Releases
  PepGen Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $19.5 million for the three months ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss was $19.5 million for the three months ended June 30, 2023
  - Result: reported results
  source text: PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2023 and highlighted recent corporate developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835597/000095017023039391/0000950170-23-039391-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.